Epkinly (epcoritamab) is a subcutaneously delivered CD3×CD20 BiTE that secured FDA accelerated approval in 2023 for r/r DLBCL.
AbbVie and Genmab’s bispecific antibody Epkinly (epcoritamab) can now be used to treat patients with relapsed or refractory follicular lymphoma, based on an FDA approval on Wednesday.
After news broke earlier this month that Danish antibody specialist Genmab would receive up to $8.4 million in state tax credits as part of a plan to grow its presence in Plainsboro, New Jersey, real estate firm Colliers has firmed up the deal.
Positive topline results were announced for the relapsed/refractory follicular lymphoma (FL) cohort of the Phase I/II EPCORE NHL-1 trial evaluating Genmab and AbbVie’s Epkinly (Epcoritamab-bysp).
Big Pharma’s competition in the anti-CD20 bispecific space is taking shape, with the FDA on Friday approving what analysts view as a best-in-class blood cancer drug.
AbbVie and Genmab's epcoritamab has won accelerated approval to treat diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. The drug now bears the commercial moniker Epkinly.